



**Parasitocidal effect of synthetic bovine Lactoferrin peptides on the enteric parasite *Giardia intestinalis***

Journal:	<i>Biochemistry and Cell Biology</i>
Manuscript ID	bcb-2016-0079.R5
Manuscript Type:	Article
Date Submitted by the Author:	16-Nov-2016
Complete List of Authors:	<p>Aguilar-Diaz, Hugo; Facultad de Medicina, Universidad Autónoma de Sinaloa, CIASaP</p> <p>Canizalez-Roman, Adrian; Facultad de Medicina, Universidad Autonoma de Sinaloa, CIASaP; Hospital de la Mujer, Departamento de Investigación Nepomuceno-Mejia, Tomas; Instituto Nacional de Salud Pública., Centro Regional de Investigación en Salud Pública</p> <p>Gallardo-Vera, Francisco; Facultad de Medicina. Universidad Nacional Autónoma de México, Departamento de Biología Celular y Tisular</p> <p>Hornelas-Orozco, Yolanda; Universidad Nacional Autónoma de México</p> <p>Nazmi, Kamran; Academic Center Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Department of Oral Biochemistry</p> <p>Bolscher, Jan; Academic Center Dentistry Amsterdam, University of Amsterdam and VU University Amsterdam, Department of Oral Biochemistry</p> <p>Carrero, Julio Cesar; Universidad Nacional Autonoma de Mexico Instituto de Investigaciones Biomedicas</p> <p>Leon-Sicairos, Claudia; Universidad Autónoma de Sinaloa, Programa Regional de Noroeste para el Doctorado en Biotecnología. FCQB</p> <p>Leon-Sicairos, Nidia; Facultad de Medicina, Universidad Autónoma de Sinaloa, CIASaP; Hospital Pediátrico de Sinaloa, Departamento de investigación</p>
Keyword:	Lactoferrin, Peptides, LFchimera, parasitocidal, Giardiasis

SCHOLARONE™  
Manuscripts

1 **Parasiticidal effect of synthetic bovine Lactoferrin peptides on**  
2 **the enteric parasite *Giardia intestinalis***

3

4 Hugo Aguilar-Diaz<sup>1</sup>, Adrian Canizalez-Roman<sup>1,2</sup>, Tomas Nepomuceno-Mejia<sup>3</sup>, Francisco  
5 Gallardo-Vera<sup>4</sup>, Yolanda Hornelas-Orozco<sup>5</sup>, Kamran Nazmi<sup>6</sup>, Jan G.M. Bolscher<sup>6</sup>, Julio  
6 Cesar Carrero<sup>7</sup>, Claudia Leon-Sicairos<sup>8</sup>, Nidia Leon-Sicairos<sup>1,9\*</sup>

7

8

9 <sup>1</sup> CIASaP, Facultad de Medicina, Universidad Autónoma de Sinaloa. Cedros y Sauces,  
10 Fracc. Fresnos Culiacán 80246, Sinaloa, México

11 <sup>2</sup> Departamento de Investigación, Hospital de la Mujer. Boulevard Miguel Tamayo  
12 Espinoza de los Monteros, S/N Col. Desarrollo Urbano Tres Ríos. Culiacán 80020, Sinaloa,  
13 México

14 <sup>3</sup> Centro Regional de Investigación en Salud Pública, Instituto Nacional de Salud Pública.  
15 Calle 4a. Avenida Norte esquina con Calle 19 Pte S/N, Centro, Tapachula 30700, Chiapas,  
16 Mexico

17 <sup>4</sup> Laboratorio Inmunobiología, Departamento de Biología Celular y Tisular, Facultad de  
18 Medicina. Universidad Nacional Autónoma de México. Ciudad Universitaria, México DF  
19 04510, México

20 <sup>5</sup> Servicio Académico de Microscopía Electrónica de Barrido. Instituto de Ciencias del Mar  
21 y Limnología, Universidad Nacional Autónoma de México, México, D. F. 04510, México

22 <sup>6</sup> Department of Oral Biochemistry, Academic Centre for Dentistry Amsterdam, University  
23 of Amsterdam and VU University, 1081 LA, Amsterdam, The Netherlands

24 <sup>7</sup> Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad  
25 Nacional Autónoma de México. Ciudad Universitaria, México, DF 04510, México

26 <sup>8</sup> Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Sinaloa, Avenida de  
27 las Américas y Josefa Ortiz (Ciudad Universitaria), Culiacán 80030, Sinaloa, México

28 <sup>9</sup> Departamento de Investigación, Hospital Pediátrico de Sinaloa. Blvd. Constitución S/N,  
29 col. Jorge Almada, Culiacan 80200, Sinaloa, México

30

31

32 *Corresponding author. Nidia León-Sicairos. Email [nidialeon@uas.edu.mx](mailto:nidialeon@uas.edu.mx)*  
33 *CIASaP, Facultad de Medicina, Universidad Autónoma de Sinaloa, Cedros y Sauces S/N*  
34 *Fracc. Fresnos. Culiacán Sinaloa, 80246 México Telephone +52 6672278588 Fax +52 66*  
35

36

37

38

39 **Abstract**

40

41 *Giardia intestinalis* is the most common infectious protozoan parasite in children. Despite  
42 the effectiveness of some drugs, the disease remains a major worldwide problem.  
43 Consequently, the search for new treatments is important for disease eradication. Biological  
44 molecules with antimicrobial properties represent a promising alternative to combat  
45 pathogens. Bovine lactoferrin (bLF) is a key component of the innate host defense system,  
46 and its peptides have exhibited strong antimicrobial activity. Based on these properties, we  
47 evaluated the parasitocidal activity of these peptides on *G. intestinalis*. Trophozoites were  
48 incubated with different peptide concentrations for different periods of time, and the growth  
49 or viability was determined by carboxyfluorescein-succinimidyl-diacetate-ester (CFDA)  
50 and propidium iodide (PI) staining. Endocytosis of peptides was investigated by confocal  
51 microscopy, damage was analyzed by transmission and scanning electron microscopy, and  
52 the type of programmed cell death was analyzed by flow cytometry. Our results showed  
53 that the LFpeptides had giardicidal activity. The LFpeptides interacted with *G. intestinalis*  
54 and exposure to LFpeptides correlated with an increase in the granularity and vacuolization  
55 of the cytoplasm. Additionally, the formation of pores, extensive membrane disruption, and  
56 programmed cell death was observed in trophozoites treated with LFpeptides. Our results  
57 demonstrate that LFpeptides exhibit potent *in vitro* anti-giardial activity.

58

59 **Keywords: Lactoferrin; LFchimera; parasitocidal; peptides; Giardia; Giardiasis**

60

61

62

## 63 Introduction

64

65 *Giardia intestinalis* (also known as *Giardia lamblia* or *Giardia duodenalis*), is a flagellated  
66 unicellular eukaryotic parasite that causes giardiasis, a diarrheal disease, throughout the  
67 world (Watkins and Eckmann 2014). Giardiasis is the most common cause of waterborne  
68 outbreaks of diarrhea in the United States and is occasionally considered a cause of food-  
69 borne diarrhea (Furness et al. 2000). In certain areas of the world, water contaminated  
70 with *G. lamblia* commonly causes travel-related giardiasis in tourists (Painter et al. 2015;  
71 Watkins and Eckmann 2014). This parasite is particularly problematic in developing  
72 countries, where a very high prevalence and incidence of infection has been reported. Data  
73 suggest that long-term growth retardation in children can result from chronic giardiasis, in  
74 part due to the parasite attaching itself to the lining of the small intestine in humans, where  
75 it interferes with the body's absorption of fats and carbohydrates from digested foods  
76 (Eckmann 2003). Giardiasis is reported more frequently in young children and  
77 immunocompromised or chronically ill individuals, and *G. intestinalis* infection is  
78 particularly significant for people with malnutrition, immunodeficiencies, or cystic fibrosis  
79 (Painter et al. 2015; Watkins and Eckmann 2014).

80

81 *Giardia* species have two major stages in their lifecycle. Infection with *G. intestinalis*  
82 initiates when the cysts are ingested with contaminated water or, less commonly, food or  
83 through direct fecal-oral contact. The cyst is relatively inert, allowing prolonged survival in  
84 a variety of environmental conditions (Adam 2001; Carranza and Lujan 2010). After  
85 exposure to the acidic environment of the stomach, cysts excyst into trophozoites in the  
86 proximal small intestine. The trophozoite (the vegetative form) replicates in the small

87 intestine, causing symptoms of diarrhea and malabsorption. After exposure to biliary fluid,  
88 some of the trophozoites form cysts in the jejunum and are passed in the feces, allowing for  
89 completion of the transmission cycle by infecting a new host (Adam 2001; Carranza and  
90 Lujan 2010).

91

92 Standard treatment for giardiasis consists of antibiotic therapy. Metronidazole is the most  
93 commonly prescribed drug for this condition. However, metronidazole use has been  
94 associated with significant failure rates in clearing parasites from the gut and with poor  
95 patient compliance (Watkins and Eckmann 2014). In addition, an increasing incidence of  
96 nitroimidazole-refractory giardiasis has been reported in travelers from India (Nabarro et al.  
97 2015). Appropriate fluid and electrolyte management is critical, particularly in patients with  
98 large-volume diarrheal losses and in children with acute or chronic diarrhea who manifest a  
99 failure to thrive, malabsorption, or other gastrointestinal tract symptoms in whom *Giardia*  
100 organisms have been identified (Dominguez-Lopez et al. 2011; Hill 1993; Vesly and  
101 Peterson 1999).

102

103 Innate-immunity mechanisms play a role in the control and/or severity of the infection;  
104 however, little is known about the mechanisms involved in this immune response  
105 (Roxstrom-Lindquist et al. 2006). Breastfeeding protects infants from *G. intestinalis*  
106 infection. Breast milk contains detectable titres of secretory IgA, which is protective for  
107 infants, especially in developing countries (Eckmann 2003; Morrow et al. 1992). A study  
108 from Egypt showed breast-fed infants had a lower incidence of symptomatic and  
109 asymptomatic infection. Furthermore, infected infants who were exclusively breast-fed had  
110 fewer clinical manifestations than those who were not exclusively breast-fed (Abdel-Hafeez

111 et al. 2013; Gendrel et al. 1989). Apart from IgA, a milk protein called lactoferrin (LF) has  
112 been reported as an immunological factor that kills trophozoites *in vitro* and *in vivo*: both  
113 hLf and bLF and peptides derived from their N-terminals (LfcinH and LfcinB) have  
114 microbicidal activity against *Giardia* (Gillin et al. 1983; Ochoa et al. 2008; Turchany et al.  
115 1995; Turchany et al. 1997). However, it is not known if synthetic bLF peptides share this  
116 activity and the mechanism of action of Lf-derived peptides is unknown. Thus, the aim of  
117 this work was to study the possible microbicidal activity of synthetic bLF-based peptides  
118 against *Giardia intestinalis* and to explore the mechanism involved in parasitical effects  
119 against *Giardia in vitro*.

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135 **Materials and methods**

136

137 **Bovine lactoferrin, synthetic peptides and chemotherapeutic agents**

138 Bovine LF (bLF, 20% iron saturated) was kindly donated by Morinaga Milk Industries Co  
139 (Tokyo, Japan). The purity of bLF (>98%) was checked by SDS-PAGE stained with silver  
140 nitrate. Lactoferrin concentration was assessed by UV spectroscopy on the basis of an  
141 extinction coefficient of 15.1 (280 nm, 1% solution). The bLF iron saturation was about  
142 20% as detected by optical spectroscopy at 468 nm on the basis of an extinction coefficient  
143 of 0.54 (100% iron saturation). LPS contamination of bLf, estimated by Limulus  
144 Amebocyte assay (LAL Pyrochrome kit, ThermoFischerScientific, Waltham, MA, USA),  
145 was equal to  $0.7 \pm 0.06$  ng/mg of bLF. Synthetic peptides LFc<sub>in</sub>17-30, LFc<sub>ampin</sub>265-284 and  
146 LFc<sub>chimera</sub> were obtained by solid-phase peptide synthesis using Fmoc chemistry, as  
147 described previously (Bolscher et al. 2012; Bolscher et al. 2009). The chemotherapeutic  
148 agents used were metronidazole and albendazole (Sigma Chemical Co., St. Louis, MO,  
149 USA). Stock solutions were prepared in phosphate-buffered saline for metronidazole and  
150 dimethyl sulphoxide (DMSO) for albendazole. The final DMSO concentration in the  
151 culture tubes was <0.5% (v/v).

152 ***Giardia intestinalis* cyst isolation**

153 Human fecal samples from different patients containing abundant *G. intestinalis* cysts were  
154 obtained from children at Hospital Pediatrico de Sinaloa in Culiacan City. *G. intestinalis*  
155 cysts were purified and concentrated from feces using a combined sucrose flotation and  
156 simplified sucrose gradient method (Hautus et al. 1988). The cysts, after being washed  
157 twice in distilled water, were resuspended in distilled water and stored at 4°C for a

158 maximum of 3 days prior to use. The *G. intestinalis*-positive cysts were confirmed by light  
159 microscopy and PCR (Elsafi et al. 2013; Stojceki et al. 2014).

#### 160 **Excystation and axenization**

161 *G. intestinalis* cysts were purified and concentrated from feces by combining the sucrose  
162 flotation method with a simplified sucrose gradient method. The excystation procedure was  
163 a modification of the Bingham and Meyer technique performed by Schupp et al. (1988).  
164 Briefly, the isolation procedure involved three steps: the concentration and cleaning of  
165 cysts by centrifugation in sucrose gradients performed 1 to 3 days after collection, the  
166 induction of excystation performed in acid solution from 1 to 5 days after cleaning cyst  
167 suspensions, and the culture and axenization in modified TYI-S-33 medium (Schupp et al.  
168 1988).

#### 169 **Viability and growth inhibition assays**

170 The effect of bLF, LFpeptides and chemotherapeutic agents on the long-term viability or  
171 permabilization of *G. intestinalis* trophozoites was determined by the inclusion of  
172 carboxyfluorescein-succinimidyl-diacetate-ester (CFDA) (St. Louis, MO, USA), or the  
173 exclusion of the dye propidium iodide (PI).

174 In one set of experiments, cultures were initiated by the addition of  $2.5 \times 10^4$   
175 trophozoites in 0.1 ml of medium to vials (15 x 45 mm) containing 3.9 ml of medium  
176 containing none (optimal viability) or one of the following agents: 1, 5, 10, 20, or 40  $\mu\text{M}$  of  
177 bLF, LFcin17-30, LFampin265-284, or LFchimera. As control of growth inhibition,  
178 treatments with metronidazole (1, 5, 10, 20, and 40  $\mu\text{M}$ ) were used. The vials were  
179 incubated at 37°C for 12 h, chilled on ice to detach trophozoites, and centrifuged at 500 g  
180 for 10 min, and the pellet was resuspended in 1 ml of medium. Long-term viability was  
181 determined using the fluorescent probe carboxyfluorescein-succinimidyl-diacetate-ester



182 (CFDA-SE) (10  $\mu\text{g/ml}$ ) and visualized by epi-fluorescence microscopy (dos Santos et al.  
183 2015). Experiments were performed at least three times in triplicate, and the mean and  
184 standard deviations are indicated. Comparison of means was done by using a two-tailed t-  
185 test for independent samples. A value of  $P < 0.05$  was considered statically significant.

186 In other experiments, *G. intestinalis* trophozoites ( $10^6$ ) were placed in tubes with  
187 TYI-S-33 and were then incubated alone (optimal viability) or with 100  $\mu\text{M}$  metronidazole,  
188 5  $\mu\text{M}$  albendazole, or 40  $\mu\text{M}$  LFcin17-30, LFampin265-284 or LFchimera for 2 h at 37° C.  
189 Membrane permeabilization by propidium iodide (PI) was used as a measure of trophozoite  
190 viability. The total number of organisms per vial was counted and compared to that of  
191 parallel untreated cultures. Experiments were performed at least three times in triplicate,  
192 and the mean and standard deviations are indicated. Comparison of means was done by  
193 using a two-tailed t-test for independent samples. A value of  $P < 0.05$  was considered  
194 statically significant.

195 Tubes with trophozoites were also incubated with combinations of metronidazole  $\pm$   
196 LFpeptides or albendazole  $\pm$  LFpeptides or LFpeptides alone. Membrane permeabilization  
197 of propidium iodide (PI) measured by flow cytometry was used as a measure of trophozoite  
198 viability.

199

## 200 **Confocal microscopy**

201 Trophozoites ( $10^6/\text{ml}$  in TYI-S-33 medium) were incubated with 2  $\mu\text{M}$  FITC-LFcin17-30,  
202 FITC-LFampim265-284 or FITC-LFchimera for 0, 5, 15, 30, 45 or 60 min at 37°C. After  
203 washing twice in cold PBS, trophozoites were collected by centrifugation, fixed with 4% *p*-  
204 formaldehyde (30 min at 37°C), permeabilized with 0.5% triton X-100, counterstained with  
205 PI, washed and processed for analysis by confocal microscopy.

### 206 **Transmission electron microscopy**

207 *G. intestinalis* trophozoites (approximately  $10^6$  cells) were untreated or treated with 40  $\mu$ M  
208 of bLF-peptides for 2 h at 37 °C. Trophozoites were collected by centrifugation and  
209 processed for standard transmission electron microscopy (Vázquez-Nin and Echeverría  
210 2000). Briefly, samples were fixed using 2.5% glutaraldehyde in PBS for 2 h at 4°C, post-  
211 fixed in 1% osmium tetroxide for 1 h, dehydrated in a graded series of ethanol, and  
212 embedded in Epon resin. Semi-thin sections (approximately 300-400 nm) were stained with  
213 toluidine blue and observed with bright-field microscopy. Sections were mounted on  
214 copper grids and contrasted with uranyl acetate and lead citrate. Samples embedded in the  
215 resin were cut with an ultramicrotome. Serial thin sections (50-60 nm width) were obtained,  
216 and the samples were then stained with uranyl acetate and lead citrate. The sections were  
217 observed with a JEOL 1010 transmission electron microscope at 80 kV.

### 218 **Scanning electron microscopy**

219 *G. intestinalis* trophozoites ( $5 \times 10^6$ ) were incubated with 40  $\mu$ M of LFpeptides for 2 h at  
220 37 °C, washed and fixed with 10% formaldehyde for 72 h. Samples were washed and then  
221 dehydrated in a graded series of ethanol. Dehydrated samples were placed in acetone and  
222 then collocated in desiccator for 30 min. Finally samples were mounted in glass chambers  
223 and bombarded with gold particles for 20 min (Perez-Rangel et al. 2013). Processed  
224 specimens were observed with a scanning electron microscope JEOL LSM6360LV.

### 225 **Flow cytometry**

226 To detect early apoptosis or programmed cell death, *G. intestinalis* trophozoites ( $5 \times 10^6$ )  
227 treated with 40  $\mu$ M LFpeptides for 2 h at 37°C were stained with Allophycocyanin-Annexin  
228 and 7-Amino-Actinomycin D (BD Pharmingen, San José, CA), following the  
229 manufacturer's instructions. Annexin V (also known as Annexin A5) and 7-AAD (7-amino-

230 actinomycin D) are indicators of early apoptosis or programmed cell death in *Giardia* and  
231 necrosis or late programmed cell death, respectively. Both fluorescent dyes were measured  
232 in *G. intestinalis* using Acoustic Focusing Cytometer Attune™ Blue/Red (Life  
233 Technologies).

234

## 235 **Results**

### 236 **Effects of bLF, LFpeptides and chemotherapeutics agents on the viability and long-** 237 **term growth of *Giardia intestinalis***

238 The effect of LFc<sub>in17-30</sub>, LFamp<sub>in265-284</sub> and LFchimera on *G. intestinalis* trophozoites  
239 was analyzed using the membrane permeabilization probe PI, as a measure of viability.  
240 When the *G. intestinalis* trophozoites were incubated with 40 μM LFpeptides for 2 h, the  
241 trophozoites showed a marked PI uptake, indicating a drastic effect on the viability (Figure  
242 1, panel A). LFchimera had the best killing effect (more than 98% of the trophozoites were  
243 stained with PI) followed by the other LFpeptides (70-80% of the trophozoites were  
244 stained) compared with untreated cells. Furthermore, the parasitocidal effect of LFchimera  
245 was higher than the drugs albendazole and metronidazole (controls of viability inhibition)  
246 (Figure 1, panel A).

247 Concentrations of 100 μM of metronidazole or 5 μM of albendazole were needed to  
248 permeate more than 95% of *G. intestinalis* cultures. However, only 20 μM and 3 μM of  
249 these drugs were needed to reach the same level of membrane permeation when 20, 30 or 5  
250 μM of LFc<sub>in17-30</sub>, LFamp<sub>in254-284</sub> or LFchimera, respectively, were added, (Table 1).  
251 Thus, the combined effect of lower concentrations of metronidazole or albendazole with  
252 LFc<sub>in17-30</sub>, LFamp<sub>in265-284</sub> or LFchimera had the best initial parasitocidal activity (Table  
253 1).

254 Next, the ability of different concentrations of LFc<sub>in17-30</sub>, LFa<sub>mpin265-284</sub> and  
255 LFc<sub>himera</sub> to inhibit long-term growth was tested using the live-stain CFDA. After 12 h of  
256 interaction, the growth of *G. intestinalis* trophozoites in the presence of 5, 10, 20 or 40  $\mu$ M  
257 of LF and LFpeptides was lower than that found in the untreated trophozoites (Figure 1,  
258 panel B). Interestingly, LFc<sub>himera</sub> had better giardicidal activity than the drug  
259 metronidazole: 40  $\mu$ M LFc<sub>himera</sub> inhibited the growth of cultures with more efficacy than  
260 40  $\mu$ M metronidazole. Similar results were obtained when *G. intestinalis* cultures were  
261 incubated with 40  $\mu$ M of each treatment for longer periods of time (24, 36 and 48 h, data  
262 not shown). Therefore, at 40  $\mu$ M LFc<sub>himera</sub> had the best parasitocidal activity, followed by  
263 40  $\mu$ M of the drug metronidazole and LFc<sub>in17-30</sub>, LFa<sub>mpin 265-284</sub>, and bLF.

264

#### 265 **LFc<sub>in17-30</sub>, LFa<sub>mpin265-284</sub> and LFc<sub>himera</sub> interact with *Giardia intestinalis***

266 The majority of live trophozoites incubated with 2  $\mu$ M FITC-Labeled LFc<sub>in17-30</sub>,  
267 LFa<sub>mpin265-284</sub> or LFc<sub>himera</sub> showed bright green fluorescence (Figure 2, panels B, C  
268 and D, respectively). Trophozoites were counterstained with PI, which exhibits red  
269 fluorescence (Figure 2, panels A-D). At 30 min, all FITC-LFpeptides were visible in the  
270 trophozoites (green fluorescence, arrowheads), suggesting that the LFpeptides were  
271 endocytosed or internalized by *G. intestinalis*. Additionally, it would appear that degraded  
272 RNA and DNA are present in the images of trophozoites treated with the peptides (B-D).  
273 The controls (untreated trophozoites) were negative for the green fluorescence (A).

274

#### 275 **Morphologic effects of LFc<sub>in17-30</sub>, LFa<sub>mpin265-284</sub> and LFc<sub>himera</sub> on *Giardia*** 276 ***intestinalis* trophozoites**

277 We examined cells after relatively short times of exposure to observe early and more direct  
278 changes, as well as those accompanying or secondary to cell lysis, by transmission electron  
279 microscopy (TEM). Untreated cells had a smooth cellular membrane (cm, double-headed  
280 arrow), peripheral vacuoles (pv, lines) near the cellular membrane, three pairs of flagella  
281 (F, discontinuous arrow), adherent disk (ad), and two nuclei (N) and two nucleoli (no)  
282 (Figure 3, panel A). Magnification of the picture shows granules of electron-dense material  
283 (asterisk) distributed in the cytoplasm and the arrangement of the microtubules belonging to  
284 the adherent disk (ad) (panel B). Exposure to LFcin17-30 led to profound intracellular  
285 changes, such as an increase in electron-dense material in the cytoplasm (asterisk),  
286 reorganization of the flagella (F, discontinuous arrow) and displacement of the adherent  
287 disk (ad, arrow), Figure 3, panel C. In the magnified picture, there are no peripheral  
288 vacuoles (pv) near the cellular membrane (cm, double-headed arrow), Panel D. Treatment  
289 with LFampin265-284 also caused intracellular damage, including an increase in electron-  
290 dense material (asterisk), reorganization of the flagella (F, discontinuous arrow), a large  
291 hole in the cytoplasm (arrowhead), and also disruption in the cellular membrane (cm,  
292 double-headed arrow) (Figure 3, panel E). The magnified picture shows the large hole  
293 induced by treatment with LFampin265-284 (arrowhead, panel F). Trophozoites treated  
294 with LFchimera produced the most significant changes and damage in the trophozoites.  
295 There were marked changes in the electron-dense material in the cytoplasm (asterisks), the  
296 flagella (F, discontinuous arrow) were disrupted and reorganized, and the cytoplasm  
297 showed large holes (arrowheads) in which some electron-dense material is visible (Figure  
298 3, panel G). In the magnified picture the largest holes (arrowheads) with aggregates inside  
299 them (asterisks) can be seen in more detail (Panel H). Shrunken and distorted peripheral  
300 vacuoles (pv, lines) were also observed.

301 *G. intestinalis* trophozoites treated with LFpeptides also were analyzed under scanning  
302 electron microscopy (SEM). Treated trophozoites exhibited damage on the cell surface  
303 (Figure 4). By SEM it was found that *G. intestinalis* cultures treated with LFc<sub>in</sub>17-30 (B),  
304 LFampin<sub>265-284</sub> (C), or LFchimera (D) showed alterations in size, irregular form and  
305 perforations (arrows) compared with untreated trophozoites (which had the typical structure  
306 of *G. intestinalis* trophozoites) (A). Additionally, the large hole in the membrane of the  
307 trophozoite treated with Lfchimera shown in panel D revealed the presence of unusual  
308 aggregates.

309

310 **LFc<sub>in</sub>17-30, LFampin<sub>265-284</sub> and LFchimera induced programmed cell death in**  
311 ***Giardia intestinalis* trophozoites**

312 LFc<sub>in</sub>17-30, LFampin<sub>265-284</sub> and LFchimera induced early programmed cell death in *G.*  
313 *intestinalis* trophozoites treated with 40 μM of these peptides for 2 h (Figure 5, panels A, B,  
314 and C, respectively). The quadrants represent Q1: Necrotic cells, Q2: Necrosis and apoptotic  
315 cells, Q3: Earlier apoptotic cells, Q4: live cells. Cells treated with LFchimera and  
316 LFampin<sub>265-284</sub> induced early programmed cell death as measured by the liberation of  
317 phosphatidylserine (PS) (Q3. 27.9 and 25.5%, respectively), and, to a lesser extent, early  
318 programmed cell death was also induced by treatment with LFc<sub>in</sub>17-30 (Q3. 7.66%).  
319 Although the total of the analyzed population were not undergoing programmed cell death,  
320 this result and the images observed under electron microscopy reinforce the idea that *G.*  
321 *intestinalis* is induced to undergo programmed cell death after treatment with LFpeptides.

322

323

324

## 325 Discussion

326 Although giardiasis has been a threat to mankind for thousands of years, this parasitic  
327 infection has been, until recently, relatively neglected. *G. intestinalis* is a major cause of  
328 parasite-induced diarrhea in humans and animals and is currently an important public health  
329 problem, mostly in developing countries but also in developed countries (Escobedo et al.  
330 2010; Painter et al. 2015). Nearly 33% of people in developing countries have had  
331 giardiasis, and nearly 2% of adults and 6% to 8% of children have giardiasis worldwide  
332 (Escobedo et al. 2010; Furness et al. 2000; Painter et al. 2015). Although giardiasis is  
333 considered by most medical practitioners to be an easily treatable infection, prolonged  
334 symptoms due to, or following, *G. intestinalis* infection can significantly impact the quality  
335 of life (Painter et al. 2015; Vesny and Peterson 1999; Watkins and Eckmann 2014).  
336 Symptom recurrence, including abdominal symptoms and fatigue, can result from re-  
337 infection, treatment failure, and disturbances in the gut mucosa or post-infection syndromes  
338 (Watkins and Eckmann 2014). In developed countries, these sequelae can have an  
339 enormous impact on the quality of life; in developing countries, particularly in children,  
340 they add yet another burden to populations that are already disadvantaged. Infection with  
341 *G. intestinalis* remains latent because only a handful of agents have been used in therapy,  
342 and the agents that are available may have adverse effects or be contraindicated in certain  
343 clinical situations. Additionally, resistance may play a role in some infections (Vesny and  
344 Peterson 1999; Watkins and Eckmann 2014). Thus, research on the development of new  
345 compounds to combat giardiasis is needed.

346

347 In this work, we demonstrated that synthetic, bLF-derived LFc<sub>in17-30</sub>, LF<sub>ampin265-284</sub>,  
348 and LFchimera have parasitocidal activity against *G. intestinalis* trophozoites *in vitro*. In

349 *in vitro* giardicidal activity of native human and bovine LF, as well as their derived N-  
350 terminal peptides, has been observed previously (Turchany et al. 1995). Treated  
351 trophozoites showed ultrastructural damage, with lactoferrin and its N-terminal peptides  
352 causing striking and complex morphologic changes in the trophozoite plasmalemma,  
353 endomembrane and cytoskeleton and increasing the electron density of the lysosome-like  
354 peripheral vacuoles (Turchany et al. 1997). The synthetic peptides used in this work are  
355 different from those reported by Turchany et al. (1995), but the giardicidal activity, the  
356 binding and endocytosis of the peptides by the trophozoites and the damage induced at the  
357 ultrastructural level were similar. Neither  $\text{Fe}^{3+}$ ,  $\text{Fe}^{2+}$ , nor other compounds such as  $\text{MgCl}_2$ ,  
358 or  $\text{CaCl}_2$ , diminished or prevented the parasiticidal activity of LFpeptides against *G.*  
359 *intestinalis* trophozoites (unpublished results). While we cannot directly compare our  
360 results with Turchany et al. (1995, 1997) because we used cultures from cysts of *G.*  
361 *intestinalis* directly isolated from patients that were forced to excyst in the laboratory, their  
362 results support our conclusion that LFpeptides exhibit potent *in vitro* anti-giardial activity.

363

364 LFchimera presented greater giardicidal activity in the viability assays and induced more  
365 pronounced damage to *G. lamblia* trophozoites at the ultrastructural level compared to its  
366 individual constituent peptides LFcin17-30 and LFampin265-284. All of the peptides at  
367 low concentrations had a dramatic parasiticidal effect when they were combined with the  
368 pharmacological drugs metronidazole or albendazole (used to treat giardiasis).

369

370 Regarding differences found with the two methods to estimate viability (PI and CFDA) in  
371 *G. intestinalis* treated with LFpeptides, LF and drugs (Figures 1 A and 1 B, respectively), it  
372 is known that the fluorogenic dye PI is unable to traverse intact cell membranes; therefore,



373 only cells with disrupted or broken membranes are counterstained by PI. Consequently, PI  
374 is an indirect indicator of cellular viability. On the other hand, it has been established that  
375 an intact lipid bilayer slows the leakage of the fluorochrome CFDA from within intact cells,  
376 while injured or stressed cells cannot retain or accumulate the fluorochrome CFDA (dos  
377 Santos et al. 2015; Schupp et al. 1988). Additionally, the replication time is different in the  
378 distinct genotypes of *G. intestinalis*; consequently, the drug sensitivity data from *in vitro*  
379 studies in Giardia varies as a function of the replication time and the methodological  
380 techniques employed (Hahn et al. 2013). Therefore, both factors (different replication times  
381 and methodologies) could explain the differences of results obtained using PI and CFDA  
382 (Figures 1 A and 1B). Despite the differences in these methodologies, it is clear that LF and  
383 LFpeptides have a parasitocidal effect on *G. intestinalis* isolates, and data obtained by  
384 electron microscopy (Figures 3 and 4, respectively) corroborate our conclusion that LF and  
385 LF peptides exhibited giardicidal activity.

386

387 Regarding the mechanism of action, our confocal microscopy observations demonstrated  
388 that LFpeptides were bound and internalized by *G. intestinalis* trophozoites (Figure 2). We  
389 speculate that the localization of peptides inside *G. intestinalis* is an event involved in the  
390 mechanism of action of LF peptides against this protozoan. It is likely that LFpeptides  
391 caused damage to membranes, including internal membranes. In agreement with this idea,  
392 LFpeptides appeared to trigger an early programmed cell death or apoptosis-like event in *G.*  
393 *intestinalis* (Figure 5).

394

395 In higher eukaryotes, programmed cell-death (PCD) is the death of a cell in any form  
396 mediated by an intracellular program. Programmed cell death is a genetically regulated

397 process that is central to the development, homeostasis and integrity of multicellular  
398 organisms (Ameisen 2002). Interestingly, several molecules or pathways that regulate PCD  
399 in higher eukaryotes have been implicated in the death of unicellular organisms (Bruchhaus  
400 et al. 2007), and apoptosis-like programmed cell death (PCD) has been described in  
401 multiple primitive eukaryotes and protists, including unicellular parasites, meaning that  
402 unicellular organisms can commit suicide in response to various stimuli (Bruchhaus et al.  
403 2007; Kaczanowski et al. 2011; van Zandbergen et al. 2010). *G. intestinalis* is a divergent  
404 amitochondrial eukaryote with a unicellular, bi-nucleated flagellated structure, but even this  
405 organism undergoes PCD (Bagchi et al. 2012). However, this is a pathway of autophagy  
406 and differs from the classical apoptosis of higher eukaryotes. Annexin-V and 7-AAD  
407 staining was used to analyze early programmed cell death in *G. intestinalis* (Bagchi et al.  
408 2012; Ghosh et al. 2009). Annexin V (or Annexin A5) is a member of the annexin family of  
409 intracellular proteins and binds to phosphatidylserine (PS). Externalization of PS is an  
410 indicator of early apoptosis-like or programmed cell death in *Giardia* (Ghosh et al. 2009).  
411 7-AAD (7-amino-actinomycin D) has a high DNA binding constant and is efficiently  
412 excluded by intact cells and bound by cells in necrosis or late programmed cell death. Both  
413 fluorescent dyes were measured in *G. intestinalis* using Acoustic Focusing Cytometer  
414 Attune™ Blue/Red (Life Technologies). Our results demonstrate that all of the peptides  
415 induced early programmed cell death in *G. intestinalis* (Figure 5). These data are  
416 corroborated by the type of damage observed at the ultrastructural level (Figure 3, Panels  
417 C-H, Figure 4, panels B-D).

418

419 There is no previous evidence of apoptosis-like or programmed cell death induced by bLF  
420 in a parasite, but it has been reported that LF triggered programmed cell death in cells

421 infected with influenza virus (Pietrantonio et al. 2010), echovirus (Tinari et al. 2005), and  
422 *Listeria monocytogenes* (Valenti et al. 1999). Additionally, LF triggers apoptosis or  
423 apoptosis-like activity in microorganisms such as *Saccharomyces cerevisiae* (Acosta-  
424 Zaldivar et al. 2016) and *Candida albicans* (Andres et al. 2008).

425

426 Further studies are needed to determine if LF and LFpeptides have an effect against *G.*  
427 *intestinalis* in *in vivo* models. However, all data to date suggest that LFpeptides are active  
428 compounds with the potential to combat giardiasis, alone or when combined with  
429 chemotherapeutic drugs.

430

#### 431 **Acknowledgments**

432 The authors thank Dr. Martha Ponce-Macotella from LPE-Instituto Nacional de Pediatría for  
433 her generous donation of clinical isolates of *Giardia intestinalis*, Dr. Luis Felipe Jimenez  
434 from Laboratorio MET-Facultad de Ciencias UNAM for his efficient technical support, and  
435 Jorge A. Canizalez-León for his support in the preparation of images. This work was  
436 supported by CONACyT México grant CB-2014-236546 (NLS). Aguilar-Diaz was a PhD  
437 student from the Programa Regional del Noroeste para el Doctorado en Biotecnología de la  
438 Universidad Autónoma de Sinaloa, and was supported by a PhD fellowship CONACyT-  
439 México (Grant 169048). Kamran Nazmi and Dr. Jan Bolscher were supported through a  
440 grant from the University of Amsterdam for research into the focal point Oral Infections  
441 and Inflammation.

442

443

444

445 **References**

- 446 Abdel-Hafeez, E.H., Belal, U.S., Abdellatif, M.Z., Naoi, K., and Norose, K. 2013. Breast-feeding  
447 protects infantile diarrhea caused by intestinal protozoan infections. The Korean journal of  
448 parasitology **51**(5): 519-524. doi: 10.3347/kjp.2013.51.5.519.
- 449 Acosta-Zaldivar, M., Andres, M.T., Rego, A., Pereira, C.S., Fierro, J.F., and Corte-Real, M. 2016.  
450 Human lactoferrin triggers a mitochondrial- and caspase-dependent regulated cell death in  
451 *Saccharomyces cerevisiae*. Apoptosis : an international journal on programmed cell death **21**(2):  
452 163-173. doi: 10.1007/s10495-015-1199-9.
- 453 Adam, R.D. 2001. Biology of *Giardia lamblia*. Clinical microbiology reviews **14**(3): 447-475. doi:  
454 10.1128/CMR.14.3.447-475.2001.
- 455 Ameisen, J.C. 2002. On the origin, evolution, and nature of programmed cell death: a timeline of  
456 four billion years. Cell death and differentiation **9**(4): 367-393. doi: 10.1038/sj/cdd/4400950.
- 457 Andres, M.T., Viejo-Diaz, M., and Fierro, J.F. 2008. Human lactoferrin induces apoptosis-like cell  
458 death in *Candida albicans*: critical role of K<sup>+</sup>-channel-mediated K<sup>+</sup> efflux. Antimicrobial agents and  
459 chemotherapy **52**(11): 4081-4088. doi: 10.1128/AAC.01597-07.
- 460 Bagchi, S., Oniku, A.E., Topping, K., Mamhoud, Z.N., and Paget, T.A. 2012. Programmed cell death  
461 in *Giardia*. Parasitology **139**(7): 894-903. doi: 10.1017/S003118201200011X.
- 462 Bolscher, J., Nazmi, K., van Marle, J., van 't Hof, W., and Veerman, E. 2012. Chimerization of  
463 lactoferricin and lactoferrampin peptides strongly potentiates the killing activity against *Candida*  
464 *albicans*. Biochem Cell Biol **90**(3): 378-388. doi: 10.1139/o11-085.
- 465 Bolscher, J.G., Adao, R., Nazmi, K., van den Keybus, P.A., van 't Hof, W., Nieuw Amerongen, A.V.,  
466 Bastos, M., and Veerman, E.C. 2009. Bactericidal activity of LFchimera is stronger and less sensitive  
467 to ionic strength than its constituent lactoferricin and lactoferrampin peptides. Biochimie **91**(1):  
468 123-132. doi: 10.1016/j.biochi.2008.05.019.
- 469 Bruchhaus, I., Roeder, T., Rennenberg, A., and Heussler, V.T. 2007. Protozoan parasites:  
470 programmed cell death as a mechanism of parasitism. Trends in parasitology **23**(8): 376-383. doi:  
471 10.1016/j.pt.2007.06.004.
- 472 Carranza, P.G., and Lujan, H.D. 2010. New insights regarding the biology of *Giardia lamblia*.  
473 Microbes and infection / Institut Pasteur **12**(1): 71-80. doi: 10.1016/j.micinf.2009.09.008.
- 474 Dominguez-Lopez, M.E., Gonzalez-molero, I., Ramirez-Plaza, C.P., Soriguer, F., and Oliveira, G.  
475 2011. [Chronic diarrhea and malabsorption due to common variable immunodeficiency,  
476 gastrectomy and giardiasis infection: a difficult nutritional management]. Nutricion hospitalaria  
477 **26**(4): 922-925. doi: 10.1590/S0212-16112011000400037.
- 478 dos Santos, S.R., Branco, N., Franco, R.M., Paterniani, J.E., Katsumata, M., Barlow, P.W., and Gallep  
479 Cde, M. 2015. Fluorescence decay of dyed protozoa: differences between stressed and non-  
480 stressed cysts. Luminescence : the journal of biological and chemical luminescence **30**(7): 1139-  
481 1147. doi: 10.1002/bio.2872.
- 482 Eckmann, L. 2003. Mucosal defences against *Giardia*. Parasite immunology **25**(5): 259-270.
- 483 Elsafi, S.H., Al-Maqati, T.N., Hussein, M.I., Adam, A.A., Hassan, M.M., and Al Zahrani, E.M. 2013.  
484 Comparison of microscopy, rapid immunoassay, and molecular techniques for the detection of  
485 *Giardia lamblia* and *Cryptosporidium parvum*. Parasitology research **112**(4): 1641-1646. doi:  
486 10.1007/s00436-013-3319-1.
- 487 Escobedo, A.A., Almirall, P., Robertson, L.J., Franco, R.M., Hanevik, K., Morch, K., and Cimerman, S.  
488 2010. Giardiasis: the ever-present threat of a neglected disease. Infectious disorders drug targets  
489 **10**(5): 329-348.

- 490 Furness, B.W., Beach, M.J., and Roberts, J.M. 2000. Giardiasis surveillance--United States, 1992-  
491 1997. MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC  
492 surveillance summaries / Centers for Disease Control **49**(7): 1-13.
- 493 Gendrel, D., Richard-Lenoble, D., Kombila, M., Gendrel, C., and Baziomo, J.M. 1989. Giardiasis and  
494 breast-feeding in urban Africa. The Pediatric infectious disease journal **8**(1): 58-59.
- 495 Ghosh, E., Ghosh, A., Ghosh, A.N., Nozaki, T., and Ganguly, S. 2009. Oxidative stress-induced cell  
496 cycle blockage and a protease-independent programmed cell death in microaerophilic *Giardia*  
497 *lamblia*. Drug design, development and therapy **3**: 103-110.
- 498 Gillin, F.D., Reiner, D.S., and Wang, C.S. 1983. Killing of *Giardia lamblia* trophozoites by normal  
499 human milk. Journal of cellular biochemistry **23**(1-4): 47-56. doi: 10.1002/jcb.240230106.
- 500 Hahn, J., Seeber, F., Kolodziej, H., Ignatius, R., Laue, M., Aebischer, T., and Klotz, C. 2013. High  
501 sensitivity of *Giardia duodenalis* to tetrahydrolipstatin (orlistat) in vitro. PloS one **8**(8): e71597. doi:  
502 10.1371/journal.pone.0071597.
- 503 Hautus, M.A., Kortbeek, L.M., Vetter, J.C., and Laarman, J.J. 1988. In vitro excystation and  
504 subsequent axenic growth of *Giardia lamblia*. Transactions of the Royal Society of Tropical  
505 Medicine and Hygiene **82**(6): 858-861.
- 506 Hill, D.R. 1993. Giardiasis. Issues in diagnosis and management. Infectious disease clinics of North  
507 America **7**(3): 503-525.
- 508 Kaczanowski, S., Sajid, M., and Reece, S.E. 2011. Evolution of apoptosis-like programmed cell  
509 death in unicellular protozoan parasites. Parasites & vectors **4**: 44. doi: 10.1186/1756-3305-4-44.
- 510 Morrow, A.L., Reves, R.R., West, M.S., Guerrero, M.L., Ruiz-Palacios, G.M., and Pickering, L.K. 1992.  
511 Protection against infection with *Giardia lamblia* by breast-feeding in a cohort of Mexican infants.  
512 The Journal of pediatrics **121**(3): 363-370.
- 513 Nabarro, L.E., Lever, R.A., Armstrong, M., and Chiodini, P.L. 2015. Increased incidence of  
514 nitroimidazole-refractory giardiasis at the Hospital for Tropical Diseases, London: 2008-2013.  
515 Clinical microbiology and infection: the official publication of the European Society of Clinical  
516 Microbiology and Infectious Diseases **21**(8): 791-796. doi: 10.1016/j.cmi.2015.04.019.
- 517 Ochoa, T.J., Chea-Woo, E., Campos, M., Pecho, I., Prada, A., McMahon, R.J., and Cleary, T.G. 2008.  
518 Impact of lactoferrin supplementation on growth and prevalence of *Giardia* colonization in  
519 children. Clinical infectious diseases : an official publication of the Infectious Diseases Society of  
520 America **46**(12): 1881-1883. doi: 10.1086/588476.
- 521 Painter, J.E., Gargano, J.W., Collier, S.A., and Yoder, J.S. 2015. Giardiasis surveillance -- United  
522 States, 2011-2012. MMWR supplements **64**(3): 15-25.
- 523 Perez-Rangel, A., Hernandez, J.M., Castillo-Romero, A., Yopez-Mulia, L., Castillo, R., Hernandez-  
524 Luis, F., Noguera-Torres, B., Luna-Arias, J.P., Radilla, G., and Leon-Avila, G. 2013. Albendazole and  
525 its derivative JVG9 induce encystation on *Giardia intestinalis* trophozoites. Parasitology research  
526 **112**(9): 3251-3257. doi: 10.1007/s00436-013-3521-1.
- 527 Pietrantoni, A., Dofrelli, E., Tinari, A., Ammendolia, M.G., Puzelli, S., Fabiani, C., Donatelli, I., and  
528 Superti, F. 2010. Bovine lactoferrin inhibits influenza A virus induced programmed cell death in  
529 vitro. Biometals: an international journal on the role of metal ions in biology, biochemistry, and  
530 medicine **23**(3): 465-475. doi: 10.1007/s10534-010-9323-3.
- 531 Roxstrom-Lindquist, K., Palm, D., Reiner, D., Ringqvist, E., and Svard, S.G. 2006. *Giardia* immunity--  
532 an update. Trends in parasitology **22**(1): 26-31. doi: 10.1016/j.pt.2005.11.005.
- 533 Schupp, D.G., Januschka, M.M., Sherlock, L.A., Stibbs, H.H., Meyer, E.A., Bemrick, W.J., and  
534 Erlandsen, S.L. 1988. Production of viable *Giardia* cysts in vitro: determination by fluorogenic dye  
535 staining, excystation, and animal infectivity in the mouse and Mongolian gerbil. Gastroenterology  
536 **95**(1): 1-10.

- 537 Stojceki, K., Sroka, J., Karamon, J., Kusyk, P., and Cencek, T. 2014. Influence of selected stool  
538 concentration techniques on the effectiveness of PCR examination in *Giardia intestinalis*  
539 diagnostics. Polish journal of veterinary sciences **17**(1): 19-25.
- 540 Tinari, A., Pietrantonio, A., Ammendolia, M.G., Valenti, P., and Superti, F. 2005. Inhibitory activity of  
541 bovine lactoferrin against echovirus induced programmed cell death in vitro. Int J Antimicrob  
542 Agents **25**(5): 433-438. doi: S0924-8579(05)00060-9 [pii] 10.1016/j.ijantimicag.2005.02.011.
- 543 Turchany, J.M., Aley, S.B., and Gillin, F.D. 1995. Giardicidal activity of lactoferrin and N-terminal  
544 peptides. Infection and immunity **63**(11): 4550-4552.
- 545 Turchany, J.M., McCaffery, J.M., Aley, S.B., and Gillin, F.D. 1997. Ultrastructural effects of  
546 lactoferrin binding on *Giardia lamblia* trophozoites. J Eukaryot Microbiol **44**(1): 68-72.
- 547 Valenti, P., Greco, R., Pitari, G., Rossi, P., Ajello, M., Melino, G., and Antonini, G. 1999. Apoptosis of  
548 Caco-2 intestinal cells invaded by *Listeria monocytogenes*: protective effect of lactoferrin.  
549 Experimental cell research **250**(1): 197-202. doi: 10.1006/excr.1999.4500.
- 550 van Zandbergen, G., Luder, C.G., Heussler, V., and Duszenko, M. 2010. Programmed cell death in  
551 unicellular parasites: a prerequisite for sustained infection? Trends in parasitology **26**(10): 477-  
552 483. doi: 10.1016/j.pt.2010.06.008.
- 553 Vázquez-Nin, G.H., and Echeverría, O.M. 2000. Introducción a la Microscopía Electrónica Aplicada  
554 a las Ciencias Biológicas. Universidad Nacional Autónoma de México Fondo de Cultura Económica.  
555 **México City.**
- 556 Vesny, C.J., and Peterson, W.L. 1999. Review article: the management of Giardiasis. Alimentary  
557 pharmacology & therapeutics **13**(7): 843-850.
- 558 Watkins, R.R., and Eckmann, L. 2014. Treatment of giardiasis: current status and future directions.  
559 Current infectious disease reports **16**(2): 396. doi: 10.1007/s11908-014-0396-y.
- 560
- 561
- 562
- 563
- 564
- 565
- 566
- 567
- 568
- 569
- 570
- 571

572 **Figure legends**

573

574 Figure 1. *LFcin17-30*, *LFampin265-284* and *LFchimera* have parasitocidal activity against  
575 *Giardia intestinalis* trophozoites. *G. intestinalis* cultures were incubated with 100  $\mu$ M  
576 Metronidazole or 5  $\mu$ M Albendazole (used as negative controls of viability) or 40  $\mu$ M  
577 LFpeptides for 2 h at 37°C (Panel A), or with different concentrations of Metronidazole  
578 (used as a negative control of culture growth), LF, or LFpeptides for 12 h at 37°C (Panel  
579 B). Then, the samples were washed and viability or culture growth was determined by the  
580 exclusion of the dye PI (A) or inclusion of CFDA (B). In both cases (A and B), untreated  
581 cultures were used as positive controls of viability or growth. Experiments were performed  
582 at least three times in triplicate. The means and standard deviations are indicated in  
583 percentages. A value of  $P < 0.05$  was considered statistically significant (\*).

584

585 Figure 2. *LFcin17-30*, *LFampin265-284* and *LFchimera* are internalized by *Giardia*  
586 *intestinalis*. Trophozoites were untreated (A) or treated with 2  $\mu$ M FITC-LFpeptides for 30  
587 min at 37 °C: *LFcin17-30* (B), *LFampin265-284* (C), and *LFchimera* (D). Then, samples  
588 were fixed, washed and permeabilized with 0.5% triton X-100 and counterstained with PI  
589 (red color). Finally, samples were processed for analysis by confocal microscopy. Arrows  
590 show the green fluorescence due to the FITC-LFpeptides (B-D). Bars 20 and 50  $\mu$ m.

591

592 Figure 3. *LFcin17-30*, *LFampin265-284* and *LFchimera* cause damage to *Giardia*  
593 *intestinalis*. Trophozoites were untreated (A, B) or treated with 40  $\mu$ M *LFcin17-30* (C, D),  
594 *LFampin265-284* (E, F), or *LFchimera* (G, H), for 2 h at 37 °C. Then, samples were



595 processed for analysis by transmission electron microscopy. The sections were analyzed  
596 and photographed using a JEOL 1010 transmission electron microscope at 80 kV.

597 Untreated cells had a smooth cellular membrane (cm, double-headed arrow), peripheral  
598 vacuoles (pv, lines) near the cellular membrane, three pairs of flagella (F, discontinuous  
599 arrow), adherent disk (ad), and two nuclei (N) and two nucleoli (no) (Figure 3, panel A).  
600 Magnification of the picture shows granules of electron-dense material (asterisk) distributed  
601 in the cytoplasm and the arrangement of the microtubules belonging to the adherent disk  
602 (ad) (panel B). Exposure to LFcin17-30 led to profound intracellular changes, such as an  
603 increase in electron-dense material in the cytoplasm (asterisk), reorganization of the flagella  
604 (F, discontinuous arrow) and displacement of the adherent disk (ad, arrow), Figure 3, panel  
605 C. In the magnified picture, there are no peripheral vacuoles (pv) near the cellular  
606 membrane (cm, double-headed arrow), Panel D. Treatment with LFampin265-284 also  
607 caused intracellular damage, including an increase in electron-dense material (asterisk),  
608 reorganization of the flagella (F, discontinuous arrow), a large hole in the cytoplasm  
609 (arrowhead), and also disruption in the cellular membrane (cm, double-headed arrow)  
610 (Figure 3, panel E). The magnified picture shows the large hole induced by treatment with  
611 LFampin265-284 (arrowhead, panel F). Trophozoites treated with LFchimera produced the  
612 most significant changes and damage in the trophozoites. There were marked changes in  
613 the electron-dense material in the cytoplasm (asterisks), the flagella (F, discontinuous  
614 arrow) were disrupted and reorganized, and the cytoplasm showed large holes (arrowheads)  
615 in which some electron-dense material is visible (Figure 3, panel G). In the magnified  
616 picture the largest holes (arrowheads) with aggregates inside them (asterisks) can be seen in  
617 more detail (Panel H). Shrunken and distorted peripheral vacuoles (pv, lines) were also  
618 observed.



619 Figure 4. *LFcin17-30*, *LFampin265-284* and *LFchimera* cause damage to *Giardia*  
620 *intestinalis*. Trophozoites were untreated (A) or treated with 40  $\mu$ M of *LFcin17-30* (B),  
621 *LFampin265-284* (C), or *LFchimera* (D) for 2 h at 37 °C. Then, samples were processed for  
622 analysis. Specimens were observed under a scanning electron microscope JEOL  
623 LSM6360LV. Trophozoites treated with LF peptides show alterations in size, irregular  
624 form and perforations (arrows, B-C), compared with untreated trophozoites (which had the  
625 typical structure of *G. intestinalis* trophozoites, A). Trophozoites treated with *LFchimera*  
626 exhibited aggregates or vesicles and several had a large hole in their membranes (arrow,  
627 panel D).

628

629 Figure 5. *Programmed cell death in Giardia intestinalis induced by LFpeptides*.  
630 Trophozoites of *G. intestinalis* were treated with 40  $\mu$ M of *LFcin17-30* (A), *LFampin265-*  
631 *284* (B) or *LFchimera* (C) for 2 h at 37 °C. Samples were stained with Allophycocyanin-  
632 Annexin (Annexin-APC, to stain Annexin V) and 7-Amino-Actinomycin D (7-AAD),  
633 processed and analyzed by flow cytometry. Q1: Necrotic cells, Q2: Necroptotic cells, Q3:  
634 Earlier apoptotic cells. Q4: live cells. One of three representative experiments is shown.

635

636

637

638

639

640

641

642

643 **Table I. Metronidazole, albendazole and LFpeptides needed alone or in combination**  
 644 **to kill >95% of *Giardia intestinalis* trophozoites**

645

646

Compounds	Concentrations ( $\mu$ M)	LFcin 17-30 ( $\mu$ M)	LFampin 265-284 ( $\mu$ M)	LFchimera ( $\mu$ M)
<i>Metronidazole</i>	<b>100</b>	-	-	-
<i>Metronidazole</i>	20	20	-	-
<i>Metronidazole</i>	20	-	30	-
<i>Metronidazole</i>	20	-	-	5
<i>Albendazole</i>	<b>5</b>	-	-	-
<i>Albendazole</i>	3	20	-	-
<i>Albendazole</i>	3	-	30	-
<i>Albendazole</i>	3	-	-	5
LFcin17-30	<b>80</b>	-	-	-
LFampin265-284	<b>80</b>	-	-	-
LFchimera	<b>40</b>	-	-	-

647

648

649

650

651

652

653

654

655

656


657

658

659

660

661 Figure 1



662

663

664

665


666

667

668

669

670 Figure 2



671

672

673

674

675

676

677

678


679

680

681

682

683 Figure 3



684


685

686

687

688 Figure 4

689



690

691

692

693

694

695

696


697

698

699

700

701 Figure 5



702

Draft